ESR1 mutations in tamoxifen-associated endometrial cancer versus spontaneous arisen endometrial tumors
An increased incidence of endometrial cancer has been described for patients that have received tamoxifen to treat breast cancer. Using samples from endometrial tumors, isolated from surgivcal specimens of patients who previously received tamoxifen treatment for breast cancer, we aimed to identify whether there are specific somatic mutations enriched in this population, relative to endometrial tumors from the general population. For this, WES was performed on matched endometrial tumors and healthy tissue (n=21).
- 42 samples
- DAC: EGAC00001002782
- Technology: Illumina HiSeq 2000
NKI Wilbert Zwart Group Data Access Committee
To request access to the datasets, please provide the following information in your Data Access Request: - Recipient and Recipient Institution - Details of dataset requested, i.e. EGA Study and Dataset Accession Number(s) - Brief abstract of the Project in which the Data will be used (500 words max.) - All Individuals who will be allowed access to the requested datasets by the Recipient Institution After receipt and review of your Data Access Request by the Data Access Committee, you will receive a Data Transfer Agreement to be completed, signed and returned to KT&C and the Data Access Committee, prior to being granted access to the requested dataset(s).” For the avoidance of doubt, the Data Access Committee reserves the right to withhold granting access.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| EGAS00001006453 | Other |
This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.